Human immune cell engraftment does not alter development of severe acute Rift Valley fever in mice.
Document Type
Article
Publication Date
7-20-2018
JAX Source
PLoS One 2018 Jul 20; 13(7):e0201104
Volume
13
Issue
7
First Page
0201104
Last Page
0201104
ISSN
1932-6203
PMID
30028878
DOI
https://doi.org/10.1371/journal.pone.0201104
Abstract
Rift Valley fever (RVF) in humans is usually mild, but, in a subset of cases, can progress to severe hepatic and neurological disease. Rodent models of RVF generally develop acute severe clinical disease. Here, we inoculated humanized NSG-SGM3 mice with Rift Valley fever virus (RVFV) to investigate whether the presence of human immune cells in mice would alter the progression of RVFV infection to more closely model human disease. Despite increased human cytokine expression, including responses mirroring those seen in human disease, and decreased hepatic viral RNA levels at terminal euthanasia, both high- and low-dose RVFV inoculation resulted in lethal disease in all mice with comparable time-to-death as unengrafted mice.
Recommended Citation
Spengler J,
McElroy A,
Harmon J,
Coleman-McCray J,
Welch S,
Keck JG,
Nichol S,
Spiropoulou C.
Human immune cell engraftment does not alter development of severe acute Rift Valley fever in mice. PLoS One 2018 Jul 20; 13(7):e0201104
Comments
The work is made available under the Creative Commons CCO public domain dedication.